ProKidney Corp. (PROK)
1.02
-0.07 (-6.85%)
At close: Mar 04, 2025, 3:59 PM
1.04
1.46%
After-hours: Mar 04, 2025, 06:01 PM EST
Company Description
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates.
It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract.
The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp.
| Country | United States |
| IPO Date | Jun 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 163 |
| CEO | Dr. Bruce Culleton M.D. |
Contact Details
Address: 2000 Frontis Plaza Blvd. Winston-Salem, North Carolina United States | |
| Website | https://www.prokidney.com |
Stock Details
| Ticker Symbol | PROK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001850270 |
| CUSIP Number | n/a |
| ISIN Number | KYG7S53R1049 |
| Employer ID | 98-1586514 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bruce Culleton M.D. | Chief Executive Officer & Director |
| Carla Poulson | Chief People Officer |
| James Coulston CPA | Chief Financial Officer |
| Richard Williams | Chief Information Officer |
| Todd C. Girolamo Esq., J.D., M.B.A. | Chief Legal Officer & Secretary |
| Anu Biswas | Senior Vice President of Manufacturing & Operations |
| Dr. Darin J. Weber Ph.D. | Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access |
| Dr. Joseph M. Stavas M.D., M.P.H. | SVice President of Clinical Affairs |
| Dr. Timothy A. Bertram D.V.M., Ph.D. | Founder |
| Dr. Ulrich Ernst Ph.D. | EVice President of Science and Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 06, 2025 | 4 | Filing |
| Feb 06, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Feb 06, 2025 | 4 | Filing |
| Jan 21, 2025 | 8-K | Current Report |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |